Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 16: Perindopril - Widerstandsarterien Abb. 17: Perindopril - Widerstandsarterien Abb. 18: Perindopril - Koronarreserve Aktuelles Bild - Abb. 19: Perindopril - Fibrinolyse Abb. 20: Perindopril - Antiatheriosklerotischer Effekt Abb. 21: Perindopril - Antiischämische Wirksamkeit Abb. 22: Perindopril - Verträglichkeit Zum letzten Bild
Abbildung 19: Perindopril - Fibrinolyse
It has been confirmed that in hypertensive and cardiovascular disease the reduced levels of tissue-type plasminogen activator (t-PA), are contributing to thrombus formation. This plays a role in the pathogenesis of acute myocardial infarction and stroke. In a recent trial which compared the effects of perindopril and losartan on fibrinolytic balance in coronary artery circulation of the patients with atypical chest pain and hypertension, perindopril increased t-PA enhanced by bradykinin significantly more than losartan.
 
Perindopril - Fibrinolyse
Vorheriges Bild Nächstes Bild   


Abbildung 19: Perindopril - Fibrinolyse
It has been confirmed that in hypertensive and cardiovascular disease the reduced levels of tissue-type plasminogen activator (t-PA), are contributing to thrombus formation. This plays a role in the pathogenesis of acute myocardial infarction and stroke. In a recent trial which compared the effects of perindopril and losartan on fibrinolytic balance in coronary artery circulation of the patients with atypical chest pain and hypertension, perindopril increased t-PA enhanced by bradykinin significantly more than losartan.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung